Feed Top Reports Pricing

⌘K

16:30:55·43d

SECFiling

SEC Form 10-Q filed by Alzamend Neuro Inc.

ALZN· Alzamend Neuro Inc.

Health Care

Full content unavailable. See the original source below.

Original source

Companies

ALZN
Alzamend Neuro Inc.
Health Care

Recent analyst ratings

Oct 1UpdateAscendiant Capital Markets$8.00

Related

SEC6d
Alzamend Neuro Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
INSIDER7d
SEC Form 4 filed by Ault Milton C Iii
PR17d
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
PR29d
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
SEC34d
Alzamend Neuro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
PR39d
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
SEC48d
SEC Form 424B5 filed by Alzamend Neuro Inc.
SEC48d
Alzamend Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022